Nanomedicine

Nanomedicine

This report analyzes the Global Market for Nanomedicine in Millions of US$ by the following Application Areas: Drug Delivery, In Vitro Diagnostics, In Vivo Imaging, Biomaterials, and Others. Annual forecasts are provided for the period of 2006 through 2015. The report profiles 263 companies including many key and niche players worldwide such as Abraxis BioScience, Inc., Acusphere, Inc., Advion Biosciences, Inc., Agilent Technologies, Inc., AMAG Pharmaceuticals, Inc., Amgen, Inc., Arrowhead Research Corporation, Calando Pharmaceuticals, Inc., Nanotope, Inc., Tego BioSciences Corporation, BioForce Nanosciences, Inc., BioSante Pharmaceuticals, Inc., Crucell N.V., Elan Corporation Plc, Elan Drug Technologies, Ensysce Biosciences, Inc., Enzon Pharmaceuticals, Inc., eSpin Technologies, Inc., Flamel Technologies S.A., Johnson & Johnson, Life Technologies Corporation, Merck & Co., Inc., Nanobiotix, NanoCarrier Co., Ltd., Nanospectra Biosciences, Inc, Nanosphere, Inc., Nanosys, Inc., Nektar Therapeutics, Novavax, Inc., Oxonica Plc, Par Pharmaceutical Companies, Inc, pSivida Limited, Starpharma Holdings Limited, Dendritic Nanotechnologies, Inc., Starpharma Pty. Ltd., and Wyeth Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Drug Delivery I-4
In Vitro Diagnostics I-4
In Vivo Imaging I-4
Biomaterials I-4
Others I-4


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
Introduction II-1
Current and Future Analysis II-1
Industry Drivers II-1
Industry Challenges II-2
Developing World Ready to Adopt Nanomedicine in a Major Way II-3
India II-3
China II-4
Japan II-4
Taiwan II-4
Nanotechnology Based Medical Products II-4
Table 1: Global Nanomedicine Market (2007): Percentage
Breakdown of Number of Nano-Based Products by Application
Area - Drug Delivery, Biomaterials, In Vivo Imaging, and
Others (includes corresponding Graph/Chart) II-5
Nanotechnology Based Drug Delivery Products II-5
Table 2: Global Nanomedicine Market (2007): Percentage
Breakdown of Number of Nano-Based Drug Delivery Products by
Category - Liposomes, Nanocristals, Virosomes, and Others
(includes corresponding Graph/Chart) II-5
Nanomedicine Patent Filings II-6
Table 3: Global Nanomedicine Market (1993-2003): Percentage
Breakdown of Nanomedicine Patents by Application Area - Drug
Delivery, In Vitro Diagnostics, Imaging, Biomaterials, and
Others (includes corresponding Graph/Chart) II-6

Table 4: Global Nanomedicine Market (1993-2003): Percentage
Breakdown of Patents by Country - US, Germany, Japan, and
Others (includes corresponding Graph/Chart) II-6

2. TRENDS & ISSUES II-7
Nanomedicine - The Future Direction II-7
Transforming Healthcare Sector Generating Demand for Nanomedicine II-7
Nanobiotechnology - A Promising Area II-8
High Demand for Tiny Healthcare Devices II-8
Research in Nanomedicine Continues to Surge II-9
Nanotechnology in Healthcare to Sustain R&D Funding II-9
Nanomedicine Clinical Pipeline to Sustain the Momentum II-10
Nanotechnology Gaining Ground in Fast Growing Drug Delivery
Market II-10
Nanotechnology - Generating More Enthusiasm Among Entrants II-11
Demand for Supplies and Devices to Grow Rapidly II-12
Nanomedicine Needs Analysis of Ethical Implications II-12
Nanotechnology-based Drug Delivery Market on an Upbeat II-12
Nanotechnology Opens Up New Frontiers in Drug Discovery II-12
Nanotechnology Raises Hope for Tuberculosis Treatment II-13
Demand for Nano-Based Medical Products to Rise Significantly II-13
Medical Nanorobotics to Raise the Standards II-13
Nanomedicine - A Useful Element in Surgical Procedures II-14
Nano-based Diagnosis and Medical Imaging Helps Treatment of
Critical Diseases II-14
More Efficient Nanoparticles Could be Made Possible by
Modeling Software II-15
Major Issues Daunting Nanomedicine Sector II-16

3. PRODUCT/TECHNOLOGY OVERVIEW II-17
Nanomedicine - A Primer II-17
Nanopores II-17
Radio-Controlled Biomolecules II-17
Quantum Dots II-18
Nanotubes II-18
Fullerenes II-19
Nanoshells II-19
Nanoprobes II-19
Nanoparticles II-19
Ceramic Nanoparticles II-20
Solid Lipid Nanoparticles II-20
Nanocapsules II-21
Dendrimers II-21
Liposomes II-21
Micelles II-21
Nanosuspensions II-22
Liquid Crystals II-22
Hydrogels II-22
Polymeric Nanoparticles II-22
Molecularly Imprinted Polymers II-23

4. APPLICATIONS II-24
Drug Delivery II-24
Targeted Nanodrug Delivery & Release II-25
Active and Passive Targeting Mechanisms in Drug Delivery II-25
Sustained and Pulsatile Release Mechanisms in Drug Delivery II-25
In Vitro Diagnostics II-26
In Vivo Imaging II-26
Biomaterials II-26
Others II-26
Drugs and Therapy II-26
Active Medical Implants II-26
Oncology II-26
Key Applications in Cancer Therapy II-27
Advanced Imaging, Early-Stage Detection, and Targeting II-27
In-vivo Imaging II-28
Effective Tracking of Process Efficiency II-28
Advancing Bioinformatics and Proteomics Research II-28
Carbon Nanotubes in Cancer Treatment II-28
Regenerative Medicine II-28
Futuristic Applications II-29
Bio-molecular Motors II-29
Genetic and Tissue Engineering II-29
External Tissue Products II-29
Internal Tissue Implants II-30
Dental and Bone Replacement II-30
Protein and Gene Analysis II-30
Nanorobot Therapeutics II-30
Lab-on-a-Chip Techniques II-31
Medical Diagnostic Sensors II-32
Nano Medical Devices - From Surgical Tools to Contact Lenses II-32
Nanoengineered Prosthetics II-32
Nanotubes - Potential Drug Delivery Vehicles II-32

5. NANOTECHNOLOGY - AN OVERVIEW II-33
Building Blocks of Nanotechnology Used, Components and Final
End-Use Products II-33
Global Nanotechnology Market II-33
Table 5: Global Nanotechnology Market (2008 & 2009):
Percentage Breakdown of Revenues by End-Use Segments -
Chemicals, Automotive, Aerospace & Defense, Semi-Conductors &
Electronics, Nanomedicine and Others (includes corresponding
Graph/Chart) II-34
Commercial Applications at an Embryonic Stage II-34
Recent Commercial Applications of Nanotechnology II-35
Nanotech Players - Germany Tops Europe While China Leads Asia -
Pacific II-36
Table 6: Nanotech Companies in Europe (2007): Number of
Players in Major Regional Markets - Germany, United Kingdom,
Switzerland, France, and Sweden (includes corresponding
Graph/Chart) II-36

Table 7: Nanotech Companies in Asia-Pacific (2007): Number of
Players in Major Regional Markets - China, South Korea,
Japan, Australia, and Taiwan (includes corresponding
Graph/Chart) II-37
Nanotech Funding by Regional Governments II-37
Table 8: Nanotech Funding by Regional Governments (2008):
Leading National Markets Ranked by Funding in US$ Million for
United States, Japan, Russia, Germany and China (includes
corresponding Graph/Chart) II-37

6. TECHNOLOGICAL DEVELOPMENTS II-38
German Scientists Develop Nanoparticle-Driven Gene Transfer
Method II-38
Oxford Sees Progress in its Novel DNA Sequencing Technology
Project II-38
Philips Releases First 3D Imaging Findings II-38
Researchers in University of Pennsylvania Invent Novel Carbon
Nanopipette II-39
UCLA Scientists Develop Localized and Controlled Drug Delivery
Method II-39
Minerva Makes New Discovery in Cancer Treatment II-40
NanoBio Releases Positive Data with NB-002 II-40
NanoBio Receives Positive Pre-Clinical Results with Intranasal
Influenza Vaccine II-41
Abraxis Announces Interim Results of Abraxane® for Metastatic
Breast Cancer II-41
Abraxis Reveals Positive Data with Abraxane® and Gemzar® II-41
BioDelivery Commences Clinical Study with Bioral® Amphotericin B II-42
NanoCarrier Develops Protein Nanoencapsulation Technology II-42
Flamel Releases Positive Preliminary Data from FT-105 Phase I
Study II-42
Abraxis Releases Positive Pre-Clinical Data with nab™
Technology Platform and SPARC Expression in Cancer Treatment II-43
American Scientists Develop Unique Nano-Based Drug Delivery
System II-43
Researchers at University of Queensland Focus to Develop Novel
Nano-based Diagnostics for Cancer Detection II-43
Indian Researchers Synthesize Polymeric Nanocurcumin for
Cancer Therapy II-44
Researchers Mull on Using Nanoparticles to Develop Anti-Tumor
Vaccines II-44
Nanomedicine Creates New Avenues for Regeneration of Nerve Cells II-44
University of Illinois Develop Enhanced Biomimetic Membranes II-45
Johns Hopkins Faculty develop Nanoparticle-Embedded Microcapsules II-45
Max Planck Research Team Develops Gold Nanoparticles II-45
Nanotechnology based Panacea for Facial Wrinkles II-45

7. PRODUCT INTRODUCTIONS/INNOVATIONS II-46
Starpharma Holdings Releases the NanoJuice™ Transfection Kit II-46
Telomolecular Introduces Nano-Based Aging Solution II-46
CytoViva® Unveils Advanced Nanotechnology Research Tool II-46
eBioscience Introduces eFluor™ Brand II-47
eBioscience Launches eFluor™ Nanocrystals II-47
BioForce Nanosciences Unveils Surface Patterning Service II-47
Eastman Kodak Unveils KODAK X-SIGHT Imaging Agents II-47
Biomet Launches NanoTite Dental Implant II-47
Deerac Introduces Equator HTS/2 Liquid Handling Solution II-48
IMEC Develops Functionalized Magnetic Nanoparticles II-48
Ivoclar Vivadent Introduces New Version of Tetric Flow II-48
Calando to Begin Human Clinical Trials for siRNA-based
Therapeutic Drug for Cancer II-49
Dabur Pharma Launches Nano-Based Drug Delivery System II-49

8. RECENT INDUSTRY ACTIVITY II-50
APR Acquires New Drug Delivery Platform II-50
Merck Inks Merger Agreement with Schering-Plough II-50
Nanobiotix to Collaborate with SonoDrugs Project Consortium II-50
Liquidia and Abbott to Jointly Develop siRNA Therapeutics II-50
Pro-Tect Acquires Medivices’ Nanotechnology Method II-51
APR to Create Dedicated Nanotechnology Unit II-51
Agilent Takes Over Nano Instruments II-51
Veridex Acquires Immunicon II-51
Thermo Fisher Takes Over nAscent II-52
Labcyte and Deerac Fluidics Combine Operations II-52
Invitrogen and Applied Biosystems Merge to Form Life Technologies II-52
Insert Therapeutics Merges with Calando Pharmaceuticals II-52
Capsulution Nanoscience and NanoDel Technologies Merge II-53
BioForce Forms Collaboration with UAlbany NanoCollege II-53
Advion and Bruker Daltonik Enter into Joint Marketing Agreement II-53
Midatech Group Inks Agreement with MonoSol Rx II-53
Advion Signs Co-Marketing Agreement with Agilent Technologies II-54
Abraxis Inks Deal to Re-Acquire US Rights to Abraxane II-54
NanoKTN and Bio Nano to Develop Nanomedicine II-54
Evolved Machines Inks License Contract with Nanosys II-54
Abraxis Bags European Commission Approval to Market Abraxane II-55
Nanogen Eyes European Molecular Diagnostics Market II-55
Abraxis Receives Approval for Marketing ABRAXANE in Korea and
China II-55
BioForce Receives MIT Validation for Nano eNabler Molecular
Printer II-55
Oxonica and Becton, Dickinson and Co. Sign Strategic Deal II-55
Nanogen Sells Royalties to DRI Capital II-56
Nanogen Signs Deal with Thermo Fisher II-56
Midatech Establishes New Nanotechnology Subsidiary II-56
Nanogen and HX Diagnostics Extend Collaboration II-57
CytImmune Joins Hands with University of Maryland II-57
Abraxis Inks Licensing Deal with Japan’s Taiho II-57
Abraxis Files Marketing Application for Abraxane in Japan II-58
BioForce Secures State Funding for ViriChip™ II-58
Capsulution and Advanced Materials Ink Patent License Deal II-58
Midatech Bags US Grant on Patent Application II-59
Nanobiotix Wins European Patent for Activable Particles II-59
Nanotherapeutics Submits IND Application for NanoDOX ™ Hydrogel II-59
Nanobiotix to Focus on Development of Diagnostics for Tropical
Diseases II-59
Ceres to Develop Novel Nanotechnology Products II-60
Batist to Commence Production of Nanotechnology- Based Bandage II-60
Unidym Creates Spin-Off Unit II-60
Avanti Creates Dedicated Targeted Drug Delivery Company II-61
Hill-Rom Chooses Anti-Microbial Technology of NanoHorizons II-61
Advion Acquires NanoTek II-61
Pioneer Surgical Acquires Angstrom Medica II-61
Arrowhead Acquires C Sixty II-62
Veritek Completes Acquisition of Omni-Lite E-Form II-62
Wyeth Extends Collaboration with Ablynx II-62
Starpharma Inks Agreement with Stiefel II-62
Nanosys Signs Collaboration Deal with Bruker Daltonics II-63
Abraxis Selects Green Cross to Commercialize Abraxane in Korea II-63
Abraxis Signs Deal to Partner California NanoSystems Institute II-63
BioForce Nanosciences Inflates Clientele Base for Nano
eNabler™ System II-64
Xidex Bags Contract to Make Carbon Nanotube Sources for
Electron Microscopes II-64
Novartis Extends Deal with AblynxII-64
BioSante Inks License Agreement with Medical Aesthetics II-64
NanoImaging Launches Imaging Services Unit II-65
Midatech Inaugurates cGMP Standard Nanoparticles Production
Facility II-65
Abraxis Announces Dedicated Proprietary Biotechnology Business II-65
Eksigent Signs Distribution Deal in Brazil II-66
NanoVic Establishes Two Nano-bio Companies II-66
Veeco Signs Collaboration Deal with Leica II-66
NanoViricides Inks CRADA with USDoD Agency II-67
Rexahn Wins Maryland Industrial Partnerships Funding II-67
Azaya Therapeutics Gains Patent for Nanotech-Based Cancer
Treatment Platform II-67
Flamel Inks Deal with Wyeth Pharmaceuticals II-67
Flamel Signs Deal with Merck Serono II-67
NanoChip® 400 Platform of Nanogen Now a GSA Schedule Product II-68
Nanogen Bags Canadian Funding for Veterinary and Bio-Terror
Diagnostics Development Project II-68
Nanogen Signs Deal in Australia for Schizophrenia Markers II-68
Wyeth Wins FDA Approval for New Labeling for Rapamune II-69
Arrowhead Infuses Capital into Tego II-69
GSK Extends Collaboration with Exelixis II-69
Oncologix Collaborates with Dendritic Nanotechnologies to
Redesign its Oncosphere Product II-70
Abraxis Signs Licensing Contract in India II-70
Abraxis Receives Australian TGA’s Acceptance to Review
Marketing Application for Abraxane® II-70
Nanotherapeutics and National Cancer Institute Sign CRADA II-71
Relisys and Cinvention Extend Licensing Agreement II-71
Lumera Extends Collaboration Pact with Medical University of
South Carolina II-71

9. FOCUS ON SELECT PLAYERS II-72
Abraxis BioScience, Inc. (US) II-72
Acusphere, Inc. (US) II-72
Advion Biosciences, Inc. (US) II-72
Agilent Technologies, Inc. (US) II-72
AMAG Pharmaceuticals, Inc. (US) II-73
Amgen, Inc. (US) II-73
Arrowhead Research Corporation (US) II-73
Calando Pharmaceuticals, Inc. (US) II-74
Nanotope, Inc. (US) II-74
Tego BioSciences Corporation (US) II-74
BioForce Nanosciences, Inc. (US) II-74
BioSante Pharmaceuticals, Inc. (US) II-75
Crucell N.V. (The Netherlands) II-75
Elan Corporation Plc (Ireland) II-75
Elan Drug Technologies (Ireland)II-76
Ensysce Biosciences, Inc. (US) II-76
Enzon Pharmaceuticals, Inc. (US) II-76
eSpin Technologies, Inc. (US) II-76
Flamel Technologies S.A. (France)II-77
Johnson & Johnson (US) II-77
Life Technologies Corporation (US) II-77
Merck & Co., Inc. (US) II-78
Nanobiotix (France) II-78
NanoCarrier Co., Ltd. (Japan) II-79
Nanospectra Biosciences, Inc. (US) II-79
Nanosphere, Inc. (US) II-79
Nanosys, Inc. (US) II-79
Nektar Therapeutics (US) II-80
Novavax, Inc. (US) II-80
Oxonica Plc (UK) II-80
Par Pharmaceutical Companies, Inc. (US) II-80
pSivida Limited (Australia) II-81
Starpharma Holdings Limited (Australia) II-81
Dendritic Nanotechnologies, Inc. (US) II-81
Starpharma Pty. Ltd. (Australia)II-81
Wyeth Pharmaceuticals, Inc. (US) II-82

10. GLOBAL MARKET PERSPECTIVE II-83
Table 9: World Recent Past, Current & Future Analysis for
Nanomedicine Market by Application Area - Drug Delivery, In
Vitro Diagnostics, In Vivo Imaging, Biomaterials and Other
Applications Independently Analyzed with Annual Revenues in
US$ Million for the Years 2006 through 2015 (includes
corresponding Graph/Chart) II-83

Table 10: World 10-Year Perspective for Nanomedicine Market by
Application Area - Percentage Breakdown of Revenues for Drug
Delivery, In Vitro Diagnostics, In Vivo Imaging, Biomaterials
and Other Applications for the Years 2006, 2009 and 2015
(includes corresponding Graph/Chart) II-84


III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 263 (including Divisions/Subsidiaries - 269)